Showing 185 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Access to healthcare

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

News
10 April 2025
Finance & funding

HIV testing requirements must be simplified for injectable PrEP to have a future

News
21 March 2025
Injectable & long-acting PrEP

Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians

News
17 March 2025
Injectable & long-acting PrEP

Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise

News
17 March 2025
Injectable & long-acting PrEP

Annual jab for HIV protection passes trial hurdle

Editor's pick
BBC News
17 March 2025
Injectable & long-acting PrEP

Cabotegravir injections for PrEP

About HIV
July 2024
Adherence

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Editor's pick
Infectious Disease Special Edition
26 June 2024
People & personal stories

Moupali Das, M.D., M.P.H., Designed the Lenacapavir Study With Black and Brown Girls in Mind

Editor's pick
TheBody
25 June 2024
Injectable & long-acting PrEP

Statement From The Gilead’s Purpose 1 Global Community Accountability Board, The African Women’s Prevention Community Accountability Board, Our Partners And Community Partners

Editor's pick
African Women’s Prevention Community Accountability Board
24 June 2024
Injectable & long-acting PrEP

No HIV infections seen in groundbreaking trial of twice-yearly injectable PrEP

News
22 June 2024
Injectable & long-acting PrEP

Unitaid calls for accelerated global access to long-acting HIV prevention drug lenacapavir after positive trial results

Editor's pick
Unitaid
21 June 2024
Injectable & long-acting PrEP

ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

Editor's pick
International Community of Women living with HIV Eastern Africa
21 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Injectable & long-acting PrEP

Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Editor's pick
AVAC
20 June 2024
Injectable & long-acting PrEP

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Editor's pick
Gilead Sciences press release
20 June 2024
HIV prevention policy

HIV prevention drug uptake is slow. Can offering choices change that?

Editor's pick
Devex (requires free registration)
20 June 2024
Injectable & long-acting PrEP

Zambia is the first country in Africa to roll out long-acting, injectable HIV prevention

Editor's pick
Gavi
5 June 2024
Injectable & long-acting PrEP

U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection

Editor's pick
National Institute of Allergy and Infectious Diseases
4 June 2024
Injectable & long-acting PrEP

Health Canada approves Apretude, the first long-acting injectable for HIV prevention

Editor's pick
CATIE
16 May 2024
Injectable & long-acting PrEP

TAF may be effective as once-weekly PrEP

News
10 May 2024
Injectable & long-acting PrEP

UK: New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents

Editor's pick
Medicines and Healthcare products Regulatory Agency (MHRA)
6 May 2024